Oncology

Only complete eradication of Helicobacter pylori infection, not treatment alone, will reduce the risk for developing stomach cancer, according to a study recently published in Gastroenterology. Shria Kumar, M.D., from the Perelman School of Medicine at the University of Pennsylvania in Philadelphia, and colleagues evaluated data for 371,813 patients from the Veterans Health Administration (median age, 62 years;...

MDNewsline recently interviewed international cancer researcher Dr. Talia Wegman to discuss the importance of molecular and genetic testing and cancer in Latinx patients. Dr Talia is a past National Cancer Institute (NCI) Division of Cancer Epidemiology & Genetics postdoctoral fellow and has been recognized in the U.S. and Mexico for her research in molecular genetics...

For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, while enzalutamide is associated with improved survival versus placebo in nonmetastatic, castration-resistant prostate cancer, according to two studies published online May 29 in the New England Journal of Medicine to coincide with the American Society...

The FDA has granted accelerated approval to Immunomedics’ Trodelvy (sacituzumab govitecan-hziy), the first antibody-drug conjugate that targets the Trop-2 antigen. Trodelvy is indicated for treatment of relapsed or refractory metastatic triple-negative breast cancer (TNBC). Chemotherapy has been the standard treatment for TNBC, and patients who take Trodelvy must have received at least 2 previous therapies for the cancer. Further clinical...

A 2018 study from the state of California found that the state’s Latino population was less likely to receive guideline recommended definite treatment for prostate cancer compared to Non-Latino white men. Latinos are the largest minority in the state of California, making up 39% of the state population. There has been a lack of information...

Per recent study, patients with B-cell NHL (non-Hodgkins Lymphoma) who failed to respond to prior treatment therapies show positive results when given mosunetuzumab, a new investigational drug. This new drug targets two proteins, one on the surface of tumor cells and the other on the surface of the recipient’s T cells. The study has been...

Black men are nearly 2.5 times more likely to be diagnosed with and die of prostate cancer compared to non-Hispanic white men.  A new study aims to debunk the long-held belief that this is due to genetic factors. JAMA Oncology’s research team led by the U-M Rogel Cancer Center analyzed data from more than 300,000...

Cellular immunotherapy is an innovative treatment approach that harnesses the body’s own immune system to fight cancer. These novel treatments are helping to transform the landscape for many current and future cancer patients.  Preclinical studies provide the first evidence that cellular immunotherapy for B cell cancers could ultimately become an off-the-shelf product, capable of being...

More than three out of four patients with multiple myeloma that had unsuccessful therapy have been found to remain in remission more than seven months after treatment with a CAR T-cell therapy targeting two proteins that are frequently found on myeloma cells. Those experiencing sustained remissions include nine patients with a difficult-to-treat form of multiple...